Find a starting point, a clinical perspective, or a closer look at the research.
24 articles
Females with Fabry disease can develop substantial organ involvement. Biochemical testing, genetic analysis and clinical assessment provide different information, and enzyme activity alone can miss the diagnosis.
SERPINA1 variants can affect lung protection and cause protein buildup in the liver. Blood levels, protein testing and genetic results answer different parts of the diagnostic question.
Wilson disease diagnosis combines clinical findings, copper studies and genetic evidence. An uncertain ATP7B result or normal ceruloplasmin cannot settle the question alone.
Discuss scope, choice and follow-up before sequencing uncovers a medically actionable result unrelated to the original question.
An FMR1 premutation is different from fragile X syndrome. It can have implications for adult health and inheritance, but it does not predict a single outcome.
A test can accurately detect the changes it was designed to find while missing others. Scope, coverage and sample choice help explain what a negative result means.
A high percentile is not an absolute risk, and strong association does not establish that using a score improves care.
A reproducible methylation pattern can support a diagnosis, but classifier coverage and validation determine how much it can resolve.
The same genetic condition can affect people differently. Penetrance and expressivity help explain what a genetic result can—and cannot—predict.
Imprinting disorders require attention to gene activity and parental origin as well as DNA sequence. Chromosome 15 illustrates the implications for testing and recurrence counselling.
CYP21A2 illustrates how similar DNA sequences and complex gene structures challenge genetic analysis—and why research methods need locus-specific validation.
Finding a DNA change is only part of the question. Clinical actionability asks whether reliable evidence supports a useful response to that finding.